期刊
CELL REPORTS
卷 37, 期 5, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2021.109942
关键词
-
类别
资金
- NIH [3RF1AG06100101S1, R21 AI143454-02S1]
- FAST GRANT-George Mason University
- CNPRC base grant [P51OD011107]
Antiviral monoclonal antibody treatment can effectively block viral replication and reduce pneumonia symptoms in high-risk populations such as the elderly and individuals with diabetes.
Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy in these populations are limited. We demonstrate that prophylactic mAb treatment blocks viral replication in both the upper and lower respiratory tracts in aged, type 2 diabetic rhesus macaques. mAb infusion dramatically curtails severe acute respiratory syndrome coronavirus 2 (SARSCoV-2)-mediated stimulation of interferon-induced chemokines and T cell activation, significantly reducing development of interstitial pneumonia. Furthermore, mAb infusion significantly dampens the greater than 3-fold increase in SARS-CoV-2-induced effector CD4 T cell influx into the cerebrospinal fluid. Our data show that neutralizing mAbs administered preventatively to high-risk populations may mitigate the adverse
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据